Kumar Singh Ankit, Kumar Adarsh, Singh Harshwardhan, Sonawane Pankaj, Pathak Prateek, Grishina Maria, Pal Yadav Jagat, Verma Amita, Kumar Pradeep
Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India.
Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, Chelyabinsk, 454008, Russia.
Chem Biodivers. 2023 Apr;20(4):e202300061. doi: 10.1002/cbdv.202300061. Epub 2023 Mar 13.
Metal complexes in cancer therapy have attracted much interest mainly because metals exhibit unique characteristics, such as redox activity, metal-ligand interaction, structure and bonding, Lewis acid properties etc. In 1965, Barnett Rosenberg serendipitously discovered the metal-based compound cisplatin, an outstanding breakthrough in the history of metal-based anticancer complexes and led to a new area of anticancer drug discovery. Many metal-based compounds have been studied for their potential anticancer properties. Some of these compounds have FDA approval for clinical use, while others are now undergoing clinical trials for cancer therapy and detection. In the present study, we have highlighted the primary mode of action of metallic complexes and all FDA-approved/under clinical trial drugs with reference to cancer treatment. This review also focuses on recent progress on metal-based complexes such as platinum, ruthenium, iron, etc. with potential anticancer activities.
金属配合物在癌症治疗中备受关注，主要是因为金属具有独特的特性，如氧化还原活性、金属-配体相互作用、结构与键合、路易斯酸性等。1965年， Barnett Rosenberg偶然发现了金属基化合物顺铂，这是金属基抗癌配合物历史上的一项杰出突破，并开创了抗癌药物发现的新领域。许多金属基化合物因其潜在的抗癌特性而得到研究。其中一些化合物已获得FDA批准用于临床，而其他一些正在进行癌症治疗和检测的临床试验。在本研究中，我们着重介绍了金属配合物以及所有已获FDA批准/正在进行临床试验的药物在癌症治疗方面的主要作用方式。本综述还关注了具有潜在抗癌活性的金属基配合物，如铂、钌、铁等的最新进展。
